High-folate diets and breast cancer survival in a prospective cohort study

Nutrition and Cancer

Volumn 44, Issue 2, 2002, Pages 139-144

  Sellers, Thomas A ^a,d   Alberts, Steven R ^a   Vierkant, Robert A ^a   Grabrick, Dawn M ^a   Cerhan, James R ^a   Vachon, Celine M ^a   Olson, Janet E ^a   Kushi, Lawrence H ^b   Potter, John D ^c  

^a MAYO CLINIC CANCER CENTER   (United States)

^b DIVISION OF RESEARCH   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; FOLIC ACID; PEMETREXED;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 0037763035     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC4402_03     Document Type: Article

References (27)

1. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, et al.: A prospective study of folate intake and the risk of breast cancer. JAMA 281, 1632-1637, 1999.
2. Rohan TE, Jain MG, Howe GR, and Miller AB: Dietary folate consumption and breast cancer risk. JNCI 92, 266-269, 2000.
3. Negri E, La Vecchia C, and Franceschi S: Dietary folate consumption and breast cancer risk. JNCI 92, 1270-1271, 2000.
4. Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, et al.: Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 12, 420-428, 2001.
5. Choi SW and Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr 130, 129-132, 2000.
6. Tucker KL, Mahnken B, Wilson PW, Jacques P, and Selhub J: Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 276, 1879-1885, 1996.
7. Cassileth BR, Lusk EJ, Strouse TB, and Bodenheimer BJ: Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med 101, 105-112, 1984.
8. Chu E and Allegra CJ: Antifolates. In Cancer Chemotherapy and Biotherapy, Chabner BA and Longo DL (eds). Philadelphia, PA: Lippincott-Raven, 1996.
9. Folsom AR, Kaye SA, Prineas RJ, Potter JP, Gapstur SM, et al.: Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 131, 794-803, 1990.
10. Bisgard KM, Folsom AR, Hong CP, and Sellers TA: Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 139, 990-1000, 1994.
11. Munger RG, Folsom AR, Kushi LH, Kaye SA, and Sellers TA: Dietary assessment of older Iowa women with a food frequency questionnaire: nutrient intake, reproducibility, and comparison with 24-hour dietary recall interviews. Am J Epidemiol 136, 192-200, 1992.
12. Ries L, Kosary C, Hankey B, Miller B, and Glegg L: SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.
13. Aapro MS: Adjuvant therapy of primary breast cancer: a review of key findings from the 7th International Conference, St. Gallen, February 2001. Oncologist 6, 376-385, 2001.
14. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53, 457-481, 1958.
15. Peto R and Peto J: Asymptotically efficient rank invariant procedures. J R Stat Soc A 135, 185-207, 1972.
16. Cox DR: Regression models and life tables. J R Stat Soc B 34, 187-202, 1972.
17. Hortobagyi GN: Management of breast cancer: status and future trends. Semin Oncol 22, 101-107, 1995.
18. Berger SH and Hakala MT: Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 25, 303-309, 1984.
19. Beardsley GP, Moroson BA, Taylor EC, and Moran RG: A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. J Biol Chem 264, 328-333, 1989.
20. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, et al.: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18, 1748-1757, 2000.
21. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, et al.: Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. JNCI 85, 1154-1159, 1993.
22. Mendelsohn LG, Gates SB, Habeck LL, Shackelford KA, Worzalla J, et al.: The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enzyme Regul 36, 365-381, 1996.
23. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, et al.: Augmentation of the therapeutic activity of lometrexol, (6R)5,10-dideazatetrahydrofolate, by oral folic acid. Cancer Res 56, 2331-2335, 1996.
24. Branda RF, Nigels E, Lafayette AR, and Hacker M: Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 92, 2471-2476, 1998.
25. Jacques PF, Sulsky SI, Sadowski JA, Phillips JCC, Rush D, et al.: Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am J Clin Nutr 57, 182-189, 1993.
26. Dijkmans BA: Folate supplementation and methotrexate. Br J Rheumatol 34, 1172-1174, 1995.
27. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98, 231-234, 2001.